Orforglipron
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 487
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Orforglipron | Hypertension | n/r | n/r | n/r | n/r |
| Placebo | Hypertension | n/r | n/r | n/r | n/r |